Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407482 | 0.80 | AURKA (0.44) | — | |
| SCHEMBL2488151 | 0.79 | AURKA (0.52) | EPHB4ACVRL1 | |
| Hydrochloric Acid SCHEMBL408539 | 0.79 | AURKA (0.43) | — | |
| SCHEMBL408013 | 0.78 | ACVRL1 (0.47) | EPHB4ACVRL1 | |
| SCHEMBL409068 | 0.77 | ACVRL1 (0.46) | EPHB4ACVRL1 | |
| SCHEMBL403501 | 0.77 | ACVRL1 (0.47) | EPHB4ACVRL1 | |
| SCHEMBL404193 | 0.76 | ACVRL1 (0.47) | EPHB4ACVRL1 | |
| SCHEMBL405832 | 0.76 | ACVRL1 (0.48) | EPHB4ACVRL1 | |
| SCHEMBL405092 | 0.75 | ACVRL1 (0.49) | EPHB4ACVRL1 | |
| SCHEMBL6517743 | 0.75 | AURKA (0.53) | EPHB4ACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367822-B1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-8853391-B2 | Tricyclic azaindoles | MERCK PATENT GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-20120022060-A1 | Tricyclic Azaindoles | MERCK PATENT GMBH (DE) | 2012-01-26 | — | — | US | disclosed |
| EP-2367822-A1 | TRICYCLIC AZAINDOLES | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010080253-A1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022060-A1 | Tricyclic Azaindoles | AZI2, DCK, PPP2CA | EPHB4 3471/4885ACVRL1 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.